Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity

Won Jin Ho(Johns Hopkins University), Qingfeng Zhu(Johns Hopkins University), Jennifer N. Durham(Johns Hopkins University), Aleksandra Popović(Johns Hopkins University), Stephanie Xavier(Johns Hopkins University), James M. Leatherman(Johns Hopkins University), Aditya Mohan(Johns Hopkins University), Guanglan Mo(Johns Hopkins University), Shu Zhang(Johns Hopkins University), Nicole Groß(Johns Hopkins University), Soren Charmsaz(Johns Hopkins University), Dongxia Lin(Fluidigm (United States)), Derek Quong(Fluidigm (United States)), Brad Wilt(Johns Hopkins University), Ihab R. Kamel(Johns Hopkins University), Matthew J. Weiss(Johns Hopkins University), Benjamin Philosophe(Johns Hopkins University), Richard A. Burkhart(Johns Hopkins University), William R. Burns(Johns Hopkins University), Chris Shubert(Johns Hopkins University), Aslam Ejaz(Johns Hopkins University), Jin He(Johns Hopkins University), Atul Deshpande(Johns Hopkins University), Ludmila Danilova(Johns Hopkins University), Genevieve Stein-O’Brien(Johns Hopkins University), Elizabeth A. Sugar(Johns Hopkins University), Daniel A. Laheru(Johns Hopkins University), Robert A. Anders(Johns Hopkins University), Elana J. Fertig(Johns Hopkins University), Elizabeth M. Jaffee(Johns Hopkins University), Mark Yarchoan(Johns Hopkins University)
Nature Cancer
July 29, 2021
Cited by 344Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis